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ABSTRACT  
Introduction  Clinical outcomes of patients with stable coronary artery disease (SCAD) may 
differ between those primarily managed by cardiologists versus non-cardiologists.  
Objectives      Our main objective was to analyze the clinical outcomes of outpatients with 
SCAD in relation to the specialty of the managing physicians.  
Patients and methods   We studied 32,468 outpatients with SCAD included in the CLARIFY 
registry, with up to 4 years follow-up data. Cardiologists provided medical care in 84.1%, and 
non-cardiologists in 15.9% of patients. Primary outcome was the composite of cardiovascular 
death, non-fatal myocardial infarction (MI), or stroke. 
Results    Important differences in demographics, clinical characteristics, and management 
were observed between groups at baseline. Patients treated by cardiologists were younger, and 
more had dyslipidemia, hypertension, and diabetes. The use of beta-blockers and 
thienopyridines, and history of PCI were more frequent in this group. More patients treated by 
non-cardiologists had a history of MI, and concomitant peripheral artery disease and 
asthma/chronic obstructive pulmonary disease. They also had a lower left ventricular ejection 
fraction, and more often received lipid-lowering drugs. After adjustment for baseline 
differences, patients treated by cardiologists had a lower risk of the primary outcome 
(adjusted HR 0.80, 95% CI 0.68–0.94; p=0.0067) and most secondary outcomes, but  greater 
risk of bleeding.  
Conclusions   Outpatients with SCAD managed by cardiologists had a lower rate of 
cardiovascular outcomes than those managed by non-cardiologists. We did not find clear 
evidence that cardiologists provided superior guideline-based treatment, so the differences in 
outcome were most likely due to unquantifiable differences in patient characteristics.  
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INTRODUCTION 
Coronary artery disease (CAD) is responsible for over half of all major cardiovascular 
events [1-3]. Patients with established stable coronary artery disease (SCAD) are generally at 
a relatively low risk of cardiovascular events. However, SCAD patients are a non-uniform 
group, and their prognosis may differ depending on demographic, clinical, geographical, and 
socioeconomic factors.  
For a broad range of diseases, there is evidence to suggest differences between 
specialists and generalists in terms of knowledge and patterns of care. Nevertheless, the effect 
of these differences on patient outcome is not well established [4]. Although the effect of 
specialty care has been relatively well addressed for patients with heart failure, and indicates 
that involvement of a cardiologist is associated with improved clinical outcome [5-7], data in 
patients with SCAD are scant [8-10]. It is therefore unclear whether differences in outcomes 
in SCAD patients primarily managed by cardiologists versus non-cardiologists exist, and if 
so, whether they are related to different patient characteristics or practice patterns. The global 
CLARIFY registry [11] provided the opportunity to explore these questions. 
We hypothesized that patients with SCAD managed by cardiologists may receive 
medical care better reflecting the current knowledge, and thus may have better clinical 
outcomes than those treated by non-specialists. 
Our objective was to analyze the demographics, clinical characteristics, management, 
and clinical outcomes of outpatients with SCAD primarily managed by cardiologists versus 
non-cardiologists in the CLARIFY registry.  
 
PATIENTS AND METHODS 
Study Design 
Detailed descriptions of the CLARIFY (ProspeCtive observational LongitudinAl 
RegIstry oF patients with stable coronary arterY disease) study have been published [11, 12]. 
Briefly, CLARIFY is a prospective, observational, longitudinal registry including over 33,000 
consecutive outpatients with SCAD from 45 countries in Europe, the Americas, Africa, the 
Middle East, and Asia/Pacific, enrolled between November 2009 and July 2010. The planned 
follow-up time is 5 years.  
Medical care was provided primarily by cardiologists or by internists/general 
practitioners, depending on the local healthcare system and patient preferences. The definition 
of cardiologist / non-cardiologist was self-defined by the recruiting physician. Each physician 
was asked to recruit 10-15 consecutive patients. The  same physician took care of the patient 
for the entire duration of the study.  
Study sites were selected with the aim of best reflecting care patterns in each country, 
taking into consideration the geographic distribution and  location (i.e. urban, suburban or 
rural). Except for China, each country had a predefined national target of 25 patients per 
million population.  
Participants had to fulfil at least one of the following criteria: a) documented previous 
myocardial infarction (MI); b) significant (>50%) stenosis on coronary arteriography; c) chest 
pain with evidence of myocardial ischemia; and d) percutaneous coronary intervention (PCI) 
or coronary artery bypass graft (CABG) >3 months before inclusion. Patients hospitalized for 
cardiovascular disease within the past 3 months, awaiting a planned revascularization, or with 
a condition hampering 5-year follow-up were excluded from the study.  
Data were collected by managing physicians at baseline and at annual visits, using 
standardized electronic case report forms.  Detailed information on data captured at baseline 
and during follow-up are presented in the Supplementary Material Online (Table S1). All data 
were transferred to the independent academic Robertson Centre for Biostatistics at the 
University of Glasgow, UK, where they were stored and analyzed. To ensure data quality, on-
site audits of 100% of the data were performed in 5% of randomly selected centers; regular telephone 
contact was maintained with investigators; and eCRFs underwent centralized verification for 
completeness, consistency, and accuracy.  
The CLARIFY Registry is registered in the ISRCTN registry of clinical trials with the number 
ISRCTN43070564. http://www.controlled-trials.com/ISRCTN43070564. 
Clinical Outcomes 
For the purpose of this analysis, the primary clinical outcome of interest was a composite 
of cardiovascular death, non-fatal MI, or non-fatal stroke within 4 years. The secondary 
outcomes included all-cause death, cardiovascular death, fatal or non-fatal MI, fatal or non-
fatal stroke, unstable angina, and major bleeding within the same period.  
Statistical Analysis 
Baseline characteristics according to the pattern of care (cardiologists versus non-
cardiologists) are presented by means of descriptive statistics, using mean ± standard 
deviation (SD) or median [interquartile range (IQR)] for continuous values, depending on data 
distribution, and number (%) for categorical data. Accordingly, Student’s t test or the 
Kruskal-Wallis test was used for between-group comparisons for continuous variables, and 
the chi-squared test, or Fisher’s exact test for categorical variables, as appropriate. Individual 
and composite clinical outcomes were analyzed based on the time to first event. The risk of 
outcomes was compared between the groups using Cox proportional hazards regression 
models to calculate hazard ratios (HRs), corresponding 95% confidence intervals (CIs) and P-
values. Data are presented as unadjusted values, and after adjustment for age, geographic 
region, sex, MI, CABG, PCI, blood pressure, left ventricular ejection fraction (LVEF), 
congestive heart failure, diabetes mellitus, peripheral artery disease (PAD), and 
asthma/chronic obstructive pulmonary disease (COPD).  
Ethics Statement 
The study was approved by the appropriate Ethics Committees, and performed according 
to the ethical standards laid down in the 1964 Declaration of Helsinki and its later 
amendments. All persons gave their written informed consent prior to inclusion in the study, 
in accordance with national and local guidelines.  
 
RESULTS 
Patient Disposition 
The study enrolled 33,230 subjects. After exclusion of patients with missing institutional 
review board approval or consent, the study population comprised 32,901 subjects. Up to 4 
years of follow-up data were available for 32,468 patients (98.7%). The information on the 
number of patients included in this analysis by country and region has been added to the 
Supplementary Material Online (Table S2). 
Medical care was provided primarily by cardiologists in 27,304 patients (84.1%), and by 
non-cardiologists in 5164 (15.9%) patients (Fig. 1). 
Patient Baseline Characteristics 
There were important differences between the two patient groups (Table 1). Notably, 
patients managed by cardiologists were marginally younger, less likely to have a history of 
MI and CABG, but more likely to have a history of PCI. Of note, less than one-quarter of the 
patients had symptoms of angina, but the prevalence of Canadian Cardiac Society (CCS) 
angina class II or III/IV was higher among patients treated by cardiologists. A higher 
proportion of cardiologist-treated patients had a history of hospitalization for heart failure; a 
higher proportion of non-cardiologist-treated patients were without heart failure symptoms. 
Both groups had a mean heart rate below 70 bpm. Blood pressure control was adequate, with 
slight (<2 mmHg) between-group differences (SBP lower and DBP higher in the cardiologist-
treated group). The mean LVEF value in the whole study population was over 50%, but lower 
in the group managed by non-cardiologists. Coronary angiography was performed more often 
in cardiologist-treated patients, and a higher proportion of these patients had multivessel 
disease.  
Among patients managed by cardiologists, there was a higher prevalence of 
dyslipidemia, hypertension, and diabetes mellitus, and patients had a lower median body mass 
index. Comorbidities, such as PAD and asthma/COPD, were more common in patients treated 
by non-cardiologists.  
Treatment  
At baseline, aspirin and calcium antagonist use was similar in both groups. Cardiologists 
more frequently used thienopyridines (mostly clopidogrel), beta-blockers, ivabradine, and 
long-acting nitrates, but less often used lipid-lowering agents and angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers (Table 2). The use of different drug classes 
and the dosage of most commonly prescribed beta-blockers in both groups at 4-year follow-up 
are presented in the Supplementary Material Online (Tables S3 and S4).  
Lipid and blood pressure control were more effective in patients treated by non-
cardiologists. Control of glycated hemoglobin in patients with diabetes mellitus was better in 
the cardiologist-managed group (Fig. 2).  
Clinical Outcomes  
The risk of the primary composite outcome of cardiovascular death, non-fatal MI, or non-
fatal stroke, in both the unadjusted and adjusted analyses was lower among patients managed 
primarily by cardiologists compared with those managed by non-cardiologists: unadjusted HR 
0.78, 95% CI 0.69–0.87 (p<0.0001); adjusted HR 0.80, 95% CI 0.68–0.94 (p=0.0067) (Fig. 
3). Likewise, the risk of a fatal or non-fatal MI (adjusted HR 0.79, 95% CI 0.63–0.99; 
p=0.045) was lower among patients treated primarily by cardiologists. Similarly, after 
adjustment, stroke and unstable angina were significantly less likely among patients treated by 
cardiologists: adjusted HR 0.73, 95% CI 0.54–0.99 (p=0.040); and adjusted HR 0.77, 95% CI 
0.67–0.88 (p=0.0001), respectively. Conversely, major bleeds – although rare – occurred 
more frequently in patients treated by cardiologists (adjusted HR 1.62, 95% CI 1.10–2.38; 
p=0.012) (Fig. 3). 
Because of the unique pattern of care in the UK, where all patients with a cardiac conditions 
are treated by primary care physicians after an initial cardiology consultation, we preformed 
sensitivity analysis on the outcome results after exclusion of the UK patients. The results were 
consisten with those in the entire study group (Supplementary Material Online, Table S5).  
 
DISCUSSION 
Our main finding is that patients with SCAD who were primarily cared for by 
cardiologists had a lower rate of the composite outcome of cardiovascular death, non-fatal MI, 
or non-fatal stroke than patients attended by non-cardiologists. This difference was robust and 
persisted after adjustment for multiple factors. Similar results were seen for fatal/non-fatal 
MI, fatal/non-fatal stroke and unstable angina. Conversely, major bleeds were more common 
among patients treated by cardiologists.  
Our findings are consistent with those reported by Go et al. [9], who analyzed the 
effects of physician specialty on knowledge, treatment, and outcomes of patients with CAD or 
heart failure. They found that patients treated by cardiologists were more likely to receive 
evidence-based care and probably had better outcomes. However, their analysis involved a 
mixed population of patients with CAD, including those with acute coronary syndromes. 
In the current study, the differences in outcomes between cardiologist- and non-
cardiologist-treated patients may have resulted from differences in baseline risk (even though 
there was adjustment for the main differences), or differences in management.  
Diabetes mellitus was better controlled in the patients managed primarily by 
cardiologists. Interestingly, however, blood pressure and lipid targets were more frequently 
met in the non-specialist group, This, paradoxically, could be due to the fact that 
cardiovascular risk in individual patients may be perceived as higher by generalists than by 
cardiologists [13]. In contrast to our findings, in previous studies [8, 10] a higher proportion 
of patients with cardiologist involvement achieved adequate lipid and blood pressure control 
versus those without cardiologist involvement. There were important differences in the use of 
evidence-based secondary prevention treatments, such as beta-blockers (greater use by 
cardiologists) and lipid-lowering drugs (greater use by non-cardiologists). While aspirin use 
did not differ, the greater proportion of patients receiving thienopyridines in the cardiologist-
managed group was most likely a reflection of the more frequent history of PCI in this group.  
It needs to be emphasized that patients in our study received adequate guideline-
recommended medical treatment, regardless of the specialty involved. In comparison, in the 
Euro Heart Survey [14], which included almost 3800 patients with SCAD enrolled by 
cardiologists, 78% were treated with aspirin, 48% with a statin, 67% with a beta-blocker, and 
37% with an angiotensin-converting enzyme inhibitor after their initial assessment. 
Revascularization rates were low, with only 13% of patients having PCI or CABG performed 
or planned [14]. 
Thus, in our study we did not find clear evidence that patients primarily treated by 
cardiologists receive better guideline-based treatment than those managed by non-
cardiologists.  
Previous studies (CLARIFY and others) have indicated that the prevalence and control 
of major cardiovascular risk factors may vary markedly by geographic region, age, sex, and 
other factors [15-19]. Thus, the differences in management patterns in our study, both 
recorded and unrecorded, might have been responsible for the better outcomes in patients 
managed by cardiologists. The second potential explanation is intrinsic differences between 
the groups. Indeed, significant differences were observed between the two groups in terms of 
demographics and medical history. Importantly, patients treated by non-cardiologists had 
more comorbid conditions, such as PAD and asthma/COPD, while in the specialist-treated 
group, CAD was a dominant problem.  
Important sex-related differences in clinical characteristics and management exist in 
all age groups of outpatients with SCAD [15, 20]. Also, patient preferences and their 
sociodemographic status may play an important role in their ability to receive specialist care 
[19]. Differences in healthcare systems between countries may be responsible for the 
availability of specialist care. For example, in the UK, outpatient care for patients with SCAD 
is provided by primary care physicians. In our study, about half of the patients managed by 
non-cardiologists came from the UK, which might have confounded our observations. 
However, sensitivity analyses excluding UK patients found consistent results.   
Although outcomes were corrected for some identified inter-group differences at 
baseline in the current study, we may not have captured all relevant factors. It is possible that 
residual confounding, unmeasured selection biases, such as social and demographic factors, 
patient preferences in receiving specialty care, and differences in patient lifestyles and 
behaviors might have contributed to our findings. 
Finally, among patients primarily managed by non-cardiologists, the degree of 
collaboration with specialists may differ. Such interaction has been shown to have a positive 
effect on outcome in patients with heart failure [21], and is also likely to play a role in patients 
with SCAD, but its degree is difficult to capture.  
Study Limitations 
Our study has several limitations: the data are observational in nature; center selection 
was made on a voluntary basis; the outcome events were not adjudicated, but were based on 
investigators’ reporting; and unmeasured confounders might have contributed to our findings. 
Conclusions 
In the contemporary global CLARIFY registry, outpatients with SCAD managed by 
cardiologists had a lower rate of cardiovascular events than those managed by non-
cardiologists. These differences were most likely due to unknown and unquantifiable 
characteristics of the type of patients managed by cardiologists compared with non-
cardiologists, as opposed to differences in the quality of care provided by cardiologists and 
non-cardiologists.  
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TABLES 
Table 1 Baseline characteristics according to cardiologist or non-cardiologist care 
characteristics cardiologist non-cardiologist P value 
 (n = 27,304) (n = 5164)  
age, years 63.9  ±10.5 65.3 ±10.0 <0.0001 
men 21,224 (77.7) 3942 (76.3) 0.026 
body mass index, kg/m
2
 27.1 [24.7–30.1] 28.4 [25.5–31.6] <0.0001 
ethnicity   <0.0001 
 Caucasian 16,775 (61.4) 4224 (81.8)  
 South Asian 2056 (7.5) 375 (7.3)  
 Chinese 2763 (10.1) 33 (0.6)  
 Japanese/Korean 1031 (3.8) 4 (0.1)  
 Hispanic 1525 (5.6) 5 (0.1)  
 Black/African 248 (0.9) 90 (1.7)  
 unknown 2906 (10.6) 433 (8.4)  
time since CAD diagnosis, years 4 [2–9] 7 [3–12] <0.0001 
medical history    
 MI 16,090 (58.9) 3329 (64.5) <0.0001 
 PCI 16,563 (60.7) 2424 (46.9) <0.0001 
 CABG 6236 (22.8) 1391 (26.9) <0.0001 
 hospitalization for heart failure 1314 (4.8) 201 (3.9) 0.0040 
 stroke 1105 (4.0) 197 (3.8) 0.43 
 asthma/COPD 1823 (6.7) 583 (11.3) <0.0001 
 family history of premature CAD 7307 (26.8) 1945 (37.7) <0.0001 
 treated hypertension 19,675 (72.1) 3394 (65.7) <0.0001 
 diabetes mellitus 8085 (29.6) 1352 (26.2) <0.0001 
 dyslipidemia 20,512 (75.1) 3782 (73.2) 0.0039 
 PAD 2644 (9.7) 556 (10.8) 0.017 
angina status   <0.0001 
 no angina 21,211 (77.7) 4039 (78.2)  
 CCS I 1575 (5.8) 486 (9.4)  
 CCS II 3372 (12.4) 470 (9.1)  
 CCS III/IV 1140 (4.2) 169 (3.3)  
coronary angiography performed 23.697 (86.8) 3993 (77.3) <0.0001 
number of vessels with >50% stenosis   <0.0001 
 0 684 (2.9) 317 (8.0)  
 1 9773 (41.3) 1599 (40.1)  
 ≥2 13.209 (55.8) 2070 (51.9)  
no heart failure symptoms 22.809 (83.5) 4745 (91.9) <0.0001 
test results    
 creatinine, mmol/l 0.088 [0.076–
0.101] 
0.088 [0.077–0.102] 0.019 
 fasting glucose, mmol/l 5.7 [5.1–6.7] 5.6 [5.0–6.4] <0.0001 
 total cholesterol, mmol/l 4.3 [3.7–5.1] 4.1 [3.6–4.8] <0.0001 
 LDL cholesterol, mmol/l 2.4 [1.9–3.0] 2.2 [1.8–2.8] <0.0001 
 ECG heart rate, bpm 67 ± 11 67 ± 12 0.74 
 ECG sinus rhythm 20,768 (95.1) 2209 (94.1) 0.091 
 SBP, mmHg 130.9 ± 16.7 131.8 ± 16.6 0.0007 
 DBP, mmHg 77.6 ± 9.9 75.8 ± 10.1 <0.0001 
 LVEF, %  56.3 ± 11.0 54.3 ± 11.2 <0.0001 
Data are presented as mean ± SD, n (%), or median [IQR]. Percentages based on number of 
patients with data available. 
Abbreviations: CABG, coronary artery bypass surgery; CAD, coronary artery disease; CCS, 
Canadian Cardiac Society; COPD, chronic obstructive pulmonary disease; DBP, diastolic 
blood pressure; ECG, electrocardiogram; IQR, interquartile range; LDL, low-density 
lipoprotein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, 
peripheral artery disease; PCI, percutaneous coronary intervention; SBP, systolic blood 
pressure; SD, standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Medical treatment at baseline according to primary cardiologist or non-cardiologist 
care 
treatment cardiologists non-cardiologists P value 
 (n = 27,304) (n = 5164)  
aspirin 23,965 (87.8) 4500 (87.2) 0.21 
thienopyridines 8112 (29.7) 638 (12.4) <0.0001 
lipid-lowering agents 25,137 (92.1) 4843 (93.8) <0.0001 
beta-blockers 20,790 (76.2) 3651 (70.7) <0.0001 
calcium antagonists 7491 (27.4) 1373 (26.6) 0.21 
long-acting nitrates 6188 (22.7) 952 (18.4) <0.0001 
ivabradine 3060 (11.2) 154 (3.0) <0.0001 
ACEI or ARB 20,749 (76.0) 4006 (77.6) 0.013 
Data are presented as n (%), and are based on the number of patients with data available. 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor 
blocker.  
 
 
 
 
 
 
 
 
 
 
FIGURE LEGENDS 
Fig. 1 Patient disposition. FU follow-up. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Proportions of patients reaching therapeutic targets. *Among those with the risk 
factor at baseline. †Patients with angina at baseline and at follow-up. BP blood pressure; 
HbA1c hemoglobin A1c; HR heart rate; LDL low-density lipoprotein. Because of poor lipid 
control described in registry data, for the LDL cholesterol we used a threshold less stringent 
than that indicated by the current guidelines.  
 
 
 
 
 
 
 
 
Fig. 3 Comparison of clinical outcomes between patients primarily managed by 
cardiologists versus non-cardiologists. *Adjusted for age, geographic region, sex, 
myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention, 
blood pressure, left ventricular ejection fraction, congestive heart failure, diabetes mellitus, 
peripheral artery disease, and asthma/chronic obstructive pulmonary disease. †Patients with 
angina at baseline and at follow-up. CV cardiovascular; MI myocardial infarction. 
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